Literature DB >> 2117505

Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates.

H J Parra1, H Mezdour, N Ghalim, J M Bard, J C Fruchart.   

Abstract

We describe a method for directly measuring LpA-I lipoprotein particles containing apolipoprotein A-I (apo A-I) not associated with apolipoprotein A-II (apo A-II), by differential electroimmunoassay of plasma on ready-to-use plates. Lipoprotein particles containing both apo A-I and apo A-II (LpA-I:A-II) are retained close to the wells when a very high excess of anti-apo A-II is used as compared with anti-apo A-I, whereas the LpA-I particles migrate and react with anti-apo A-I. The method is specific, rapid, and precise. Within- and between-run CVs at three concentrations (high, medium, and low) ranged between 1.51% and 2.72% and 3.01% and 4.56%, respectively. Analytical recovery of isolated LpA-I was from 93% to 115%. Results correlate well with those obtained by two-phase electroimmunoassay, enzyme-linked differential-antibody immunosorbent assay, and immunoaffinity chromatography coupled to enzyme-linked immunosorbent assay. The average normolipidemic concentration of LpA-I was 600 mg/L in 45 women and 490 mg/L in 40 men (P less than 0.0001).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117505

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

1.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

2.  The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM Study.

Authors:  J F Moreel; G Roizes; A E Evans; D Arveiler; J P Cambou; C Souriau; H J Parra; E Desmarais; J C Fruchart; P Ducimetière
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

3.  A unique genetic and biochemical presentation of fish-eye disease.

Authors:  J A Kuivenhoven; E J van Voorst tot Voorst; H Wiebusch; S M Marcovina; H Funke; G Assmann; P H Pritchard; J J Kastelein
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

5.  Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group.

Authors:  P Knudsen; J Eriksson; S Lahdenperä; J Kahri; L Groop; M R Taskinen
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

6.  Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones.

Authors:  A Kessling; S Ouellette; O Bouffard; A Chamberland; C Bétard; E Selinger; M Xhignesse; S Lussier-Cacan; J Davignon
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

7.  Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

Authors:  A Hiukka; E Leinonen; M Jauhiainen; J Sundvall; C Ehnholm; A C Keech; M R Taskinen
Journal:  Diabetologia       Date:  2007-07-26       Impact factor: 10.122

8.  Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.

Authors:  D J Rader; K Ikewaki; N Duverger; H Schmidt; H Pritchard; J Frohlich; M Clerc; M F Dumon; T Fairwell; L Zech
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia : A Comparison with Gemfibrozil.

Authors:  M van Dam; A F Stalenhoef; J Wittekoek; M D Trip; M H Prins; J J Kastelein
Journal:  Clin Drug Investig       Date:  2001-03       Impact factor: 2.859

Review 10.  The concept of apolipoprotein-defined lipoprotein families and its clinical significance.

Authors:  Petar Alaupovic
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.